Conteltinib (CT-707) in patients with advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, first-in-human phase 1 study

BACKGROUND: Conteltinib (CT-707) is a potent second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) showing promising anti-tumor activities in preclinical studies. This study aimed to assess the safety, pharmacokinetic (PK), and efficacy of conteltinib in patients with AL...

Descripción completa

Detalles Bibliográficos
Autores principales: Xing, Puyuan, Zhao, Qian, Zhang, Li, Wang, Hanping, Huang, Dingzhi, Hu, Pei, Sun, Yinghui, Shi, Yuankai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9694544/
https://www.ncbi.nlm.nih.gov/pubmed/36424628
http://dx.doi.org/10.1186/s12916-022-02646-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9694544/
https://www.ncbi.nlm.nih.gov/pubmed/36424628
http://dx.doi.org/10.1186/s12916-022-02646-0

Ejemplares similares